Results 21 to 30 of about 766,818 (299)
Molecules, 2021 Blockade of the programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction is currently the focus in the field of cancer immunotherapy, and so far, several monoclonal antibodies (mAbs) have achieved encouraging outcomes in cancer ...
Hongbo Zhang +9 more
doaj +1 more source
PD-1, gender, and autoimmunity [PDF]
Autoimmunity Reviews, 2010 Programmed death 1 (PD-1) and its ligands (PD-L1 and PD-L2) are responsible for inhibitory T cell signaling that helps mediate the mechanisms of tolerance and immune homeostasis. The PD-1:PD-L signaling pathway has been shown to play an important role in a variety of diseases, including autoimmune conditions, chronic infection, and cancer.
Ravi K, Dinesh +2 more
openaire +2 more sources
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? [PDF]
, 2019 Background: The immune response in melanoma patients is locally affected by presence of tumor-infiltrating lymphocytes (TILs), generally divided into brisk, nonbrisk, and absent.
Badalamenti G. +11 more
core +1 more source
Zhongliu Fangzhi Yanjiu, 2020 Malignant melanoma is the most serious type of skin cancer with a high recurrence rate and death rate. Surgery still is the cornerstone of treatment for patients with stage Ⅱ and Ⅲ melanoma.
ZOU Hanhui, Li Tao
doaj +1 more source
Journal of Hematology & Oncology, 2021 CD19-directed chimeric antigen receptor T cell (CART19) therapy is efficient and approved for relapsed/refractory diffuse large B cell lymphoma (DLBCL).
Chunmeng Wang +10 more
doaj +1 more source
Current Opinion in Pharmacology, 2015 Tumors may adopt normal physiologic checkpoints for immunomodulation leading to an imbalance between tumor growth and host surveillance. Antibodies targeting the PD-1/PD-L1 checkpoint have shown dynamic and durable tumor regressions, suggesting a rebalancing of the host-tumor interaction.
Joel, Sunshine, Janis M, Taube
openaire +2 more sources
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]
, 2015 Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core +2 more sources
Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. [PDF]
, 2020 Although immunotherapies have achieved remarkable salutary effects among subgroups of advanced cancers, most patients do not respond. We comprehensively evaluated biomarkers associated with the "cancer-immunity cycle" in the pan-cancer setting in order ...
Dressman, Devin +13 more
core +1 more source
Critical Care, 2016 Increasing evidence suggests that after the first pro-inflammatory hours, sepsis is characterized by the occurrence of severe immunosuppression. Several mechanisms have been reported to participate in sepsis-induced immune alterations affecting both innate and adaptive immunity.
Monneret, Guillaume +2 more
openaire +3 more sources
Unexpected curative effect of PD-1 inhibitor in gastric cancer with brain metastasis: A case report
Frontiers in Oncology, 2023 BackgroundGastric cancer (GC) is the third most common cause of cancer-related death in the world. Several clinical trials have proven that the use of PD-1/PD-L1 inhibitors can improve the survival of late-stage GC patients and is suggested in NCCN and ...
Qijun Wang +32 more
doaj +1 more source